XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration

Published:2024-01-10 Issue:3 Volume:13 Page:725-738
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Korobelnik Jean-François^ORCID,Chaudhary Varun,Mitchell Paul,Kang Se Woong,Tadayoni Ramin,Allmeier Helmut,Lee JinKyung,Zhang Xin,Machewitz Tobias,Bailey Clare

Funder

Bayer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40123-023-00867-x.pdf

Reference27 articles.

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.

2. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.

3. Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57–65.

4. Ohji M, Lanzetta P, Korobelnik J-F, et al. Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison. Adv Ther. 2020;37(5):2184–98.

5. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99.